kabutan

RIBOMIC Inc.(4591) Summary

4591
TSE Growth
RIBOMIC Inc.
79
JPY
0
(0.00%)
Dec 5, 12:49 pm JST
0.50
USD
Dec 4, 10:49 pm EST
Result
PTS
outside of trading hours
79.1
Dec 5, 12:34 pm JST
Summary Chart Historical News Financial Result
PER
PBR
1.26
Yield
ー%
Margin Trading Ratio
Stock Price
Dec 5, 2025
Opening Dec 5, 9:00 am
80 JPY 0.51 USD
Previous Close Dec 4
79 JPY 0.50 USD
High Dec 5, 9:20 am
81 JPY 0.52 USD
Low Dec 5, 9:05 am
79 JPY 0.50 USD
Volume
200,300
Trading Value
0.02B JPY 0.10M USD
VWAP
79.94 JPY 0.52 USD
Minimum Trading Value
7,900 JPY 50 USD
Market Cap
4.08B JPY 0.03B USD
Number of Trades
100
Liquidity & Number of Trades
As of Dec 5, 2025
Liquidity
Slightly High
1-Year Average
474
1-Year High Jan 8, 2025
8,347
Margin Trading
Date Short Interest Long Margin Positions Ratio
Nov 28, 2025 0 7,137,100
Nov 21, 2025 0 7,237,500
Nov 14, 2025 0 7,900,900
Nov 7, 2025 0 8,001,000
Oct 31, 2025 0 7,911,200
Company Profile
RIBOMIC Inc. is a drug discovery venture originating from the University of Tokyo. The company develops molecular targeted drugs utilizing RNA and collaborates with major pharmaceutical companies.
Sector
Pharmaceuticals
RIBOMIC Inc. is a biotech venture company specializing in the development of aptamer drugs (molecular targeted therapies) originating from the University of Tokyo. The company conducts innovative research and development of aptamer drugs using its proprietary "RiboART System" technology platform. Its main pipeline includes the clinical development of umedaptanib pegol for age-related macular degeneration and achondroplasia. RIBOMIC is also developing multiple aptamer drug candidates for conditions such as pulmonary arterial hypertension and proliferative vitreoretinopathy. In the ophthalmology field, the company has a joint research agreement with the University of Tokyo. Additionally, through collaborations with pharmaceutical companies and in-house drug discovery efforts, RIBOMIC aims to create treatments for diseases with high unmet medical needs.